Lenvatinib plus sintilimab with or without transarterial chemoembolization for intermediate or advanced stage hepatocellular carcinoma: a propensity score-matching cohort study.
Year: 2023
Type: article
Study design: Observational Study
Abstract: =0.000). No significant differences in the incidence of grade ≥3 TRAEs were reported between the two treatment groups. In conclusion, triple combination therapy with TLS improved survival with an acceptable safety profile compared with LS in patients with intermediate or advanced stage HCC.
Source: PubMed Central
Authors: Mengran Lang, Leijuan Gan, Shaohua Ren, Ruyu Han, Xiaochen Ma, Guangtao Li, Huikai Li, Ti Zhang, Qiang Wu, Yunlong Cui, Wei Zhang, Feng Fang, Qiang Li, Wei Lu, Tianqiang Song
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W4383710636